NCT06830317 (GAVE) is a clinical trial of Endoscopic Radiofrequency treatment in GAVE - Gastric Antral Vascular Ectasia, sponsored by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis.

What drugs are being tested in NCT06830317?

Interventions in NCT06830317: Endoscopic Radiofrequency treatment, QoL EQ5D questionaire.

What condition does NCT06830317 study?

NCT06830317 studies GAVE - Gastric Antral Vascular Ectasia.

Is NCT06830317 still recruiting?

NCT06830317 is currently not yet recruiting. Last updated 17 February 2025.

Last reviewed 2025-02-17 · How we verify

NCT06830317: GAVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on the Efficacy of Endoscopic Radiofrequency Treatment in Reducing the Need for Blood Transfusions in GAVE

Not yet recruiting Last updated 17 February 2025

What this trial tests

trial testing Endoscopic Radiofrequency treatment in GAVE - Gastric Antral Vascular Ectasia in 80 participants. Not yet recruiting.

Timeline

2 April 2025

Primary endpoint
2 July 2027

2 September 2027

Quick facts

Lead sponsor	Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	80
Start date	2 April 2025
Primary completion	2 July 2027
Estimated completion	2 September 2027

Drugs / interventions tested

Endoscopic Radiofrequency treatment
QoL EQ5D questionaire

Conditions studied

GAVE - Gastric Antral Vascular Ectasia — all drugs for GAVE - Gastric Antral Vascular Ectasia →

Sponsor

Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

Who can join

18 and older, any sex, with GAVE - Gastric Antral Vascular Ectasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study therefore is to permanently resolve the existence of the bleeding sites caused by Gave and reduce both bleeding episodes and the need for transfusion in such patients applying "Barrx" (trademark) radiofrequency endoscopic ablation technology in selected cohort of patients that will be defined the patient inclusion section.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis trials

Trials by the same sponsor.

NCT07497789 — SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases · not yet recruiting
NCT07412444 — EVOO and Metabolic Liver Health in MASLD · NA · not yet recruiting
NCT07153458 — Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer · recruiting
NCT06931925 — Recall of a Cohort of Subjects in the Mediterranean Area. Monitoring of Liver Diseases (NUTRIHEP 3). · not yet recruiting
NCT06615817 — Intermittent Fasting, Mediterranean Diet and NAFLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06830317 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Last refreshed: 17 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06830317.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing